Standard Biotools Inc.
LAB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001162194
In the last 90 days, Standard Biotools Inc. insiders filed 1 open-market purchase and 0 sales; 143 institutions reported holding it in 13F filings for Q2 2026, worth $243.6M in total; Viking Global Investors is the only superinvestor holding it.
Key figures
- Market capClose on Nov 10, 2026
- $262.5M
- Insider buysLast 90 days, $46.9K in total
- 1
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −10 vs. previous quarter
- 143
- 13F valueReported value at the end of Q2 2026
- $243.6M
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $85.3M
- −51.1% year over year
- Net income, FY2025
- -$74.9M
- No comparable prior period
- Free cash flow, FY2025
- -$82.6M
- No comparable prior period
- Revenue, Q3 FY2026
- $19.4M
- −0.9% year over year
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: $74.9M (87.8% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 2.17M
- Shares sold short
- Change
- −275.9K
- −11.3% vs. previous
- Days to cover
- 3.07
- At average daily volume
Superinvestors holding LAB, Q2 2026
Go to the superinvestors tab1 superinvestor reports holding Standard Biotools Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Viking Global Investors
Andreas Halvorsen
0.1%
Standard Biotools Inc.'s share of the portfolio
- Shares
- 58,651,170
- Value
- $48.3M
Latest insider trades
See all insider tradesOpen-market purchases and sales by Standard Biotools Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 5, 2026 (view filing)5:36 PM ET | Nov 5 | Same day | Carey Thomas D.Director | PPurchase | +75.0K | $0.6253 | +$46.9K | +21.8%419.5K after | |
| Dec 4, 2025 (view filing)8:59 PM ET | Dec 2-4 | 2 days | Casdin Partners GP, LLC and 7 othersDirector, 10% Owner | PPurchaseCommon Stock, $0.001 par value per share | +350.0K | $1.44 | +$502.6K | +0.5%72.1M after | 3 lots |
| Nov 26, 2025 (view filing)4:58 PM ET | Nov 24-25 | 2 days | Casdin Partners GP, LLC and 7 othersDirector, 10% Owner | PPurchaseCommon Stock, $0.001 par value per share | +7.70M | $1.31 | +$10.1M | +12.0%71.8M after | 2 lots |
| Nov 20, 2025 (view filing)7:45 PM ET | Nov 18-20 | 2 days | Casdin Partners GP, LLC and 7 othersDirector, 10% Owner | PPurchaseCommon Stock, $0.001 par value per share | +1.07M | $1.28 | +$1.37M | +1.7%64.0M after | 3 lots |
| Nov 17, 2025 (view filing)6:58 PM ET | Nov 13-17 | 4 days | Casdin Partners GP, LLC and 7 othersDirector, 10% Owner | PPurchaseCommon Stock, $0.001 par value per share | +925.0K | $1.22 | +$1.13M | +1.5%63.0M after | 3 lots |
| Nov 12, 2025 (view filing)7:46 PM ET | Nov 7-12 | 5 days | Casdin Partners GP, LLC and 7 othersDirector, 10% Owner | PPurchaseCommon Stock, $0.001 par value per share | +1.18M | $1.17 | +$1.38M | +1.9%62.0M after | 4 lots |
| Sep 11, 2025 (view filing)9:03 PM ET | Sep 9 | 2 days | Casdin Partners GP, LLC and 7 othersDirector, 10% Owner | PPurchaseCommon Stock, $0.001 par value per share | +100.0K | $1.29 | +$128.9K | +0.2%60.9M after | |
| Sep 5, 2025 (view filing)7:08 PM ET | Sep 3-4 | 2 days | Casdin Partners GP, LLC and 7 othersDirector, 10% Owner | PPurchaseCommon Stock, $0.001 par value per share | +500.0K | $1.27 | +$635.8K | +0.8%60.8M after | 2 lots |
| Aug 26, 2025 (view filing)8:46 PM ET | Aug 22-26 | 4 days | Casdin Partners GP, LLC and 7 othersDirector, 10% Owner | PPurchaseCommon Stock, $0.001 par value per share | +525.0K | $1.25 | +$658.8K | +0.9%60.3M after | 3 lots |
| Aug 15, 2025 (view filing)9:18 PM ET | Aug 13-15 | 2 days | Casdin Partners GP, LLC and 7 othersDirector, 10% Owner | PPurchase | +358.2K | $1.24 | +$443.0K | +0.6%59.8M after | 3 lots |
Top 10 13F holders, Q2 2026
See all 143 holdersThe largest institutional positions in Standard Biotools Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Casdin Capital, LLC | 88,783,856 | $73.0M | 3.66% | 00.0% | Unchanged |
| Viking Global Investors LPSuperinvestorViking Global Investors | 58,651,170 | $48.3M | 0.14% | 00.0% | Unchanged |
| Mak Capital One LLC | 28,813,904 | $23.7M | 3.32% | +2,641,278+10.1% | Added |
| Long Focus Capital Management, LLC | 23,500,000 | $19.3M | 0.79% | +7,484,279+46.7% | Added |
| Vanguard Capital Management LLC | 12,252,998 | $10.1M | 0.00% | −563,072−4.4% | Reduced |
| BlackRock, Inc. | 8,254,443 | $6.79M | 0.00% | −16,501,641−66.7% | Reduced |
| Hollow Brook Wealth Management LLC | 5,503,381 | $4.53M | 0.90% | −150,000−2.7% | Reduced |
| Neuberger Berman Group LLC | 4,958,620 | $4.04M | 0.00% | +301,035+6.5% | Added |
| Qube Research & Technologies Ltd | 4,820,463 | $3.97M | 0.00% | +4,116,056+584.3% | Added |
| Royce & Associates LP | 4,525,333 | $3.72M | 0.03% | +1,519,804+50.6% | Added |
Holders of 5% or more of LAB
See all 5 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Standard Biotools Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Casdin Capital, LLC | 13D/A | 23.90%93.8M shares | −0.30 ppfrom 24.20% | Apr 8, 20229 filings | Jun 9, 2026 | SEC |
| Viking Global Investors LPSuperinvestorViking Global Investors | 13D | 15.00%58.7M shares | 0.00 ppfrom 15.00% | Apr 14, 20228 filings | Jun 12, 2026 | SEC |
| Mak Capital One LLC | 13G/A | 7.30%28.8M shares | – | Aug 14, 20261 filing | Aug 14, 2026 | SEC |
| MAK Capital Fund LP | 13G/A | 6.70%26.2M shares | +1.51 ppfrom 5.19% | Jan 7, 20262 filings | May 15, 2026 | SEC |
| Long Focus Capital Management, LLC | 13G | 6.00%23.5M shares | New | Aug 14, 20261 filing | Aug 14, 2026 | SEC |